𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index

✍ Scribed by Maryska L.G. Janssen-Heijnen; Dick Johan van Spronsen; Valery E.P.P. Lemmens; Saskia Houterman; Kees D.G.W. Verheij; Jan Willem W. Coebergh

Book ID
108673196
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
172 KB
Volume
129
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Application of the international prognos
Application of the international prognostic index in a study of chinese patients with non-hodgkin's lymphoma and a high incidence of primary extranodal lymphoma
✍ Tony S. Mok; Joyce Steinberg; Anthony T. Chan; Winnie M. Yeo; P. Hui; Thomas W. πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 193 KB πŸ‘ 3 views

## Background: Chemotherapy containing anthracycline is the standard initial treatment for aggressive non-hodgkin's lymphoma (nhl), and the international prognostic index (ipi) is widely accepted as the standard tool for determining the prognosis of patients with this disease. however, the data on

CEOP treatment results and validity of t
CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma
✍ C. S. Chim; Y. L. Kwong; A. K. W. Lie; C. K. Lee; R. Liang πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 125 KB πŸ‘ 2 views

From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m 2 ) was used in place of doxorubicin (50 mg/m 2 ), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age wa